Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Protalix Biotherapeutics Inc V.PLX.H


Primary Symbol: PLX

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.


NYSEAM:PLX - Post by User

Comment by ohbehaveon Sep 05, 2019 4:28pm
230 Views
Post# 30099788

RE:RE:Keep the good news coming

RE:RE:Keep the good news coming
Frankly I'm not a fan of selling what appears to be a good asset that's adding production and cash flow with every new well but when the market isnt there to access capital a management team needs to do what it believes must be done in the best interest of its shareholders. Given the companies understanding of this new play and the fact they claim to have several other similar prospects to develope, one would hope management believes it's better to cash out of this REX play (at the right price), lose a partner that's likely pushing to do more than they can afford at this time, then pursue one of the other similar bypassed pay opportunities in the portfolio. That being the case, if your glass is half full not half empty, one could argue that as shareholders we should take comfort in the fact they understand the Mannville/REX play well enough that they're prepared to sell the "bird in hand" and focus on "two in the bush" so to speak. All I know for sure (and what I've said before) is that unless/until Canadian federal politics change the traditional market for junior O&G is broken and all the chatter on this board predicting and finger pointing about the stock price is irrelevant. The fact that the PLX stock price has dropped by 50% since early June on less than 1MM traded shares (only about 1% of the float) means nothing and given any real interest the stock price could go the other way quickly. There's no "trade" in this stock it's a buy and hold and those trading a few hundred shares need to find a different playground while the longs that understand this market (or lack thereof) need patience. From thier vast knowledge and connections, if the "all wise" posters that spew nothing but negativity truly know this is a terrible company headed for bankruptcy then what is your purpose in posting here? Contribute something of value or move on because despite all the prognostications and doomsday predictions the news has actually been (mostly) good of late.
<< Previous
Bullboard Posts
Next >>